Allergic
asthma, a chronic inflammatory disease of the airways, is characterized by the presence of T helper 2 cells and eosinophils in sputum, bronchoalveolar lavage, and mucosal biopsy specimens. Although the T helper 1-promoting
cytokine,
interleukin-12, is capable of inhibiting the T helper 2-driven
asthma symptoms and bronchial responsiveness, the specific mechanisms underlying these
interleukin-12 actions are unclear. The
anti-allergic response to
interleukin-12 is only partially dependent on
interferon-gamma, which induces apoptosis by enhancing expression of
Fas antigen. We therefore investigated in vivo whether the
anti-allergic action of
interleukin-12 is mediated through induction of apoptosis. C57BL/6 mice immunized to
ovalbumin by
intraperitoneal injection were challenged three times with an
ovalbumin aerosol every second day for 7 days. Recombinant
interleukin-12 was administered intravenously after the final challenge. After the last
ovalbumin challenge, mice were examined for effects of
interleukin-12 on inflammatory cell infiltration and apoptosis in the lung as detected by
terminal deoxynucleotidyl transferase-mediated deoxyribonucleoside
triphosphate nick end-labelling. Administration of
interleukin-12 reduced
ovalbumin-induced
pulmonary eosinophilia (P < 0.01) and CD4+ T cell infiltration (P < 0.01). Moreover, treatment with
interleukin-12 shortly after
ovalbumin inhalation resulted in both increased
interferon-gamma production (P < 0.01) and enhanced apoptosis of CD4+ T cells in allergic airway infiltrates (P < 0.05). These results suggest that the beneficial effects of
interleukin-12 in
asthma may include enhancement of apoptosis of CD4+ T cells in airways.